Much is at stake for the health of the American population in the upcoming 2020 elections. Drug pricing, a critical driver of access to medications - pending this election outcome – is on the line.

As a candidate in 2016, President Trump ran on prescription drug prices, stressing the need for government negotiations on aligning prices paid in the United States with lower prices paid in other countries. Biden's approach focuses on reducing launch prices of new drugs, lowering prices of existing drugs, and alleviating patients’ out-of-pocket costs.

There are several areas of similarity between the candidates’ proposals. However, despite many common elements, there are differences. President Trump’s proposals to address drug prices and affordability largely focus on Medicare patients; he has few policies that would directly impact prices paid by Medicaid, commercial, or uninsured patients. Alternatively, Vice President Biden has proposed to apply the policies to patients outside Medicare.

This analysis from the CommonWealth fund reviews the proposals and implications on how President Trump and Vice President Biden would approach prescription drug pricing in the United States.